HC Wainwright Reaffirms Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “neutral” rating reissued by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $1.00 price target on the stock. HC Wainwright’s price objective points to a potential downside of 17.36% from the company’s current price.

Separately, Bank of America cut Lyell Immunopharma from a “buy” rating to an “underperform” rating and decreased their price objective for the stock from $6.00 to $1.00 in a report on Wednesday, October 30th.

Lyell Immunopharma Price Performance

Shares of Lyell Immunopharma stock opened at $1.21 on Tuesday. Lyell Immunopharma has a 1 year low of $0.85 and a 1 year high of $3.26. The company has a market capitalization of $309.76 million, a P/E ratio of -1.53 and a beta of -0.47. The business has a 50 day moving average price of $1.22 and a 200 day moving average price of $1.70.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.03. Lyell Immunopharma had a negative return on equity of 33.54% and a negative net margin of 323,792.09%. The firm had revenue of $0.03 million during the quarter. As a group, research analysts expect that Lyell Immunopharma will post -0.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LYEL. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Lyell Immunopharma in the first quarter worth $64,000. Intech Investment Management LLC acquired a new position in Lyell Immunopharma during the 3rd quarter worth approximately $52,000. Dimensional Fund Advisors LP boosted its holdings in Lyell Immunopharma by 197.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock worth $58,000 after acquiring an additional 26,635 shares during the period. ProShare Advisors LLC raised its stake in shares of Lyell Immunopharma by 9.3% during the first quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock valued at $109,000 after purchasing an additional 4,170 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Lyell Immunopharma by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock worth $68,000 after purchasing an additional 19,287 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.